<DOC>
	<DOCNO>NCT00884169</DOCNO>
	<brief_summary>This study investigate efficacy safety M518101 male female plaque psoriasis patient refractory plaque .</brief_summary>
	<brief_title>Study Investigate Efficacy Safety M518101 Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Who able willing give sign informed consent Who male female age 18 65 year plaque psoriasis confirm Investigator . Who less 20 % body surface area ( BSA ) afflict plaque Who neither pregnant breastfeeding , plan become pregnant study . Who history allergy vitamin D3 derivative preparation . Who history relevant drug hypersensitivity . Who history contact dermatitis induce topical medicine . Who pregnant lactating . Who renal hepatic insufficiency , clinically significant cardiac , renal hepatic disease . Who clinically relevant history presence disease surgical history psoriasis likely affect conduct study . Whose serum calcium level exceed upper limit reference range Who use investigational medicinal product and/or participate clinical study within 24 week Who treat systemic therapy within 8 week Who treat biologics within 12 week Who treat topical therapy washout leadin period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>